Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated diseases  BARCELONA, Spain--(BUSINESS WIRE)--Almirall...

ExxonMobil's Liza projects have been honored with the International Petroleum Technology Conference (IPTC) Excellence in Project Integration Award, recognizing outstanding achievements in executing oil and gas projects.  The award, presented during the 2024 IPTC in Dhahran, Nepal, highlighted the company's...

ExxonMobil will be taking the Liza field offline to hook up the pipeline for Guyana’s Gas-to-Energy (GtE) project in the latter half of the year, but this is only expected to last weeks.  “I would say it's going to be...

Guyana’s Natural Resources Minister, Vickram Bharrat, has confirmed to OilNOW that studies are underway to determine which of ExxonMobil’s Stabroek Block projects can utilize the additional capacity of the Gas-to-Energy pipeline, following start-up in 2025. Mr. Bharrat said, “The Liza...

– Newly published data highlights additional efficacy endpoints from trial – – Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years with functional constipation –BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare...

• Conference call and webcast to be held tomorrow, January 2, at 8:30am ET (5:30am PT)LA JOLLA, Calif.--(BUSINESS WIRE)--$LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced...

– PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial – – Confirmatory trial found PADCEV plus pembrolizumab nearly doubled median overall survival compared to standard of care platinum-based chemotherapy –NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas...

SBM Offshore has secured a US$210 million revolving credit facility (RCF) to finance the construction of Fast4Ward® Multi-Purpose Floater (MPF) hulls, the company said in December 15 release.  The tenor of the RCF is eighteen months with an extension option...

SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi SAR443579 induced clinical benefit in patients with R/R AML with 5 complete...

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients. Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET) MARSEILLE, France--(BUSINESS WIRE)--#immunotherapy--Innate Pharma SA (Euronext...